


CFL-120

Cat. No.:	HY-W041315
CAS No.:	18711-15-4
Molecular Formula:	C ₈ H ₃ Cl ₂ NO ₂
Molecular Weight:	216.02
Target:	Ras
Pathway:	GPCR/G Protein; MAPK/ERK Pathway
Storage:	<div> <div>Powder</div> <div>-20°C 3 years</div> <div>4°C 2 years</div> </div> <div> <div>In solvent</div> <div>-80°C 6 months</div> <div>-20°C 1 month</div> </div>



BIOLOGICAL ACTIVITY

Description	CFL-120 is a potent KRas ^{G12C} inhibitor. CFL-120 shows an antiproliferative effect. CFL-120 shows anticancer activity. CFL-120 has the potential for the research of lung cancer ^[1] .														
IC ₅₀ & Target	KRAS(G12C)														
In Vitro	<p>CFL-120 (72 h) shows an antiproliferative effect with IC₅₀s of 11.0, 23.6, 13.7, 16.9, 44.4, 14.8, 38.0, 30.0, 13.1, 9.8, 47.9, 24.4, 42.7 μM for H1792, SW1573, MiaPaca2, H358, A549, SW480, PANC-1, LCLC-103H, BxPC3, HCA-7, MRC-5, HUVEC-TERT, CCD-986Sk cells, respectively^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>														
In Vivo	<p>CFL-120 (5 mg/kg, 5 treatments; 15 mg/kg, 5 treatments; 30 mg/kg, 3 treatments; i.p.) reduces tumor growth in subcutaneous H1792 (KRasG12C mutant) and LCLC-103H (KRasWT) human lung cancer-bearing mice^[1].</p> <p>Pharmacokinetic Parameters of CFL-120 in NOD-SCID female mice^[1].</p> <table> <tr> <th>PK parameters</th><th>CFL-137</th></tr> <tr> <td>C_{max} (ng/mL)</td><td>337 ± 123</td></tr> <tr> <td>T_{max} (h)</td><td>0.25</td></tr> <tr> <td>AUC_t (ng/mL*h)</td><td>169 ± 56</td></tr> <tr> <td>t_{1/2} (h)</td><td>4.4 ± 0.6</td></tr> <tr> <td>V_d (mL)</td><td>12,096 ± 4000</td></tr> <tr> <td>CL(mL/h)</td><td>1895 ± 539</td></tr> </table> <p>NOD-SCID female mice, 15 mg/kg IP^[1].</p>	PK parameters	CFL-137	C _{max} (ng/mL)	337 ± 123	T _{max} (h)	0.25	AUC _t (ng/mL*h)	169 ± 56	t _{1/2} (h)	4.4 ± 0.6	V _d (mL)	12,096 ± 4000	CL(mL/h)	1895 ± 539
PK parameters	CFL-137														
C _{max} (ng/mL)	337 ± 123														
T _{max} (h)	0.25														
AUC _t (ng/mL*h)	169 ± 56														
t _{1/2} (h)	4.4 ± 0.6														
V _d (mL)	12,096 ± 4000														
CL(mL/h)	1895 ± 539														

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID female mice (KRasWT (LCLC-103H) or KRasG12C (H1792) tumors) ^[1]
Dosage:	5 mg/kg, 5 treatments; 15 mg/kg, 5 treatments; 30 mg/kg, 3 treatments
Administration:	I.p.
Result:	Reduced tumor growth compared to the control group in KRasG12C mutated model for 35.8%.

REFERENCES

[1]. Orgován Z, et al. Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency. Eur J Med Chem. 2023 Mar 15;250:115212.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA